Kenneth W Draper

US Patent:

20020177568, Nov 28, 2002

Filed:

May 23, 2001

Appl. No.:

09/864785

Inventors:

Dan Stinchcomb - Ft. Collins CO, US
James McSwiggen - Boulder CO, US
Kenneth Draper - Reno NV, US

International Classification:

C07H021/04
A61K048/00

US Classification:

514/044000, 536/023200

Abstract:

The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, allozymes and antisense, which modulate the expression or function of NFKB genes, such as REL-A, REL-B, REL (c-rel), NFKB1 (p105/p50) and NFKB2 (p100)/p52/p49).

US Patent:

20030068301, Apr 10, 2003

Filed:

Jun 8, 2001

Appl. No.:

09/877478

Inventors:

Kenneth Draper - Reno NV, US
Lawrence Blatt - Boulder CO, US
James McSwiggen - Boulder CO, US
David Morrissey - Boulder CO, US

International Classification:

A61K038/21
C07H021/02
A61K048/00

US Classification:

424/085600, 514/044000, 424/085700, 536/023100

Abstract:

Nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an RNA encoding one or more protein components of Hepatitis B virus (HBV), and methods for their use alone or in combination with other therapies, such as 3TC (Lamivudine) and Interferons are disclosed.

US Patent:

20030162264, Aug 28, 2003

Filed:

Dec 23, 2002

Appl. No.:

10/325403

Inventors:

James Thompson - Lafayette CO, US
Kenneth Draper - Reno NV, US

Assignee:

Ribozyme Pharmaceuticals, Inc.

International Classification:

C07H021/02
C12P019/34
C12N015/00
C12N005/06

US Classification:

435/091100, 435/325000, 536/023100, 435/320100

Abstract:

The present invention relates to an enzymatic RNA molecule which cleaves mRNA derived from c-myc gene.

US Patent:

20040054156, Mar 18, 2004

Filed:

Jan 15, 2003

Appl. No.:

10/342902

Inventors:

Kenneth Draper - Reno NV, US
Lawrence Blatt - Boulder CO, US
James McSwiggen - Boulder CO, US
David Morrissey - Boulder CO, US

International Classification:

C07H021/02
C12N005/08
A61K048/00

US Classification:

536/023100, 435/366000, 424/093210

Abstract:

The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an RNA encoding one or more protein components of Hepatitis B virus (HBV), and methods for their use alone or in combination with other therapies, such as 3TC (Lamivudine) and Interferons are disclosed.

US Patent:

20040127446, Jul 1, 2004

Filed:

Sep 23, 2003

Appl. No.:

10/669841

Inventors:

Lawrence Blatt - San Francisco CA, US
Dennis Macejak - Arvada CO, US
James McSwiggen - Boulder CO, US
David Morrissey - Boulder CO, US
Pamela Pavco - Lafayette CO, US
Patrice Lee - Erie CO, US
Kenneth Draper - Reno NV, US
Elisabeth Roberts - Federal Heights CO, US

International Classification:

A61K048/00
C07H021/02

US Classification:

514/044000, 536/023720

Abstract:

The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an HCV or HBV RNA and methods for their use alone or in combination with other therapies. In addition, nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences and methods for their use alone or in combination with other therapies, are disclosed. Oligonucleotides that specifically bind the Enhancer I region of HBV DNA are further disclosed. The present invention further relates to the use of nucleic acids, such as decoy and aptamer molecules of the invention, to modulate the expression of Hepatitis B virus (HBV) genes and HBV viral replication. Furthermore, HBV animal models and methods of use are disclosed, including methods of screening for compounds and/or potential therapies directed against HBV. The present invention also relates to compounds, including enzymatic nucleic acid molecules, ribozymes, DNAzymes, nuclease activating compounds and chimeras such as 2′,5′-adenylates, that modulate the expression and/or replication of hepatitis C virus (HCV).

US Patent:

55917208, Jan 7, 1997

Filed:

Nov 19, 1992

Appl. No.:

7/927506

Inventors:

Kevin P. Anderson - Carlsbad CA
Kenneth G. Draper - Richmond OH

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

A61K 3170
G07H 2104

US Classification:

514 44

Abstract:

Compositions and methods for modulating the effects of cytomegalovirus (CMV) infections are disclosed, comprising contacting CMV mRNA with an oligonucleotide or oligonucleotide analog which can bind with at least portions of the CMV RNA. In accordance with the preferred embodiments, oligonucleotides or oligonucleotide analogs are designed to bind with portions of the CMV mRNAs which code for the IE1, IE2 or DNA polymerase proteins. In accordance with a preferred embodiment, methods of treatment of human cytomegalovirus are disclosed.

US Patent:

63100444, Oct 30, 2001

Filed:

Apr 28, 1992

Appl. No.:

7/852132

Inventors:

Kenneth G. Draper - San Marcos CA
David J. Ecker - Carlsbad CA
Christopher K. Mirabelli - Encinitas CA
Stanley T. Crooke - Carlsbad CA

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

A61K 4800
C07H 2104
C12Q 168
C12P 1934

US Classification:

514 44

Abstract:

Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a gene corresponding to one of the open reading frames UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42 AND UL52 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site; it is also preferred that they comprise the sequence CAT. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide specifically hybridizable with RNA or DNA deriving from one of the foregoing genes of the herpesvirus are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

US Patent:

52486702, Sep 28, 1993

Filed:

Feb 26, 1990

Appl. No.:

7/485297

Inventors:

Kenneth G. Draper - San Marcos CA
David J. Ecker - Carlsbad CA
Christopher K. Mirabelli - Encinitas CA
Stanley T. Crooke - Carlsbad CA

Assignee:

ISIS Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

A61K 3170
C07H 2100
C07H 2102
C07H 2104

US Classification:

514 44

Abstract:

Antisense oligonucleotides are disclosed having a length of 15-30 nucleotides containing the CAT sequence and hybridizable to herpes simplex virus type I gene UL13, UL39, or UL40. These antisense oligomers inhibit the replication of the virus at least three-fold. Pharmaceutical compositions containing these oligonucleotides as the active ingredients are also disclosed.

Address:

9615 Aidan Way, Reno, NV 89521

VIN:

JF1GD61667H516244

Make:

SUBARU

Model:

IMPREZA SEDAN NATL 2.0

Year:

2007